Please assess the completion status of the following clinical trial:

Trial Title: Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria~1. Age ≥ 18 years~2. Diagnosis of CMT1 or CMTX confirmed by:~   1. Clinical presentation and electrodiagnostics~  2. Genetically-confirmed CMT1 or CMTX for the patient or first-degree relative~3. Part 1:~   1. Six-minute walk distance (6MWD) of at least 150 meters (without a brace or walker)~  2. Independent ambulation for at least 10 meters, without a brace~  3. Left and right ankle plantar flexion MRC grade 4+ to 5, inclusive~   Part 2:~  1. 6MWD ≥ 150 and ≤ 500 meters (without a brace or walker); a maximum of 20% of enrolled patients with 6MWD ≥ 450 meters will be included~  2. Left and right ankle plantar flexion MRC grade 4- to 5, inclusive~4. Left and right ankle dorsiflexion Medical Research Council (MRC) manual muscle testing (MMT) grade 3 to 4+ inclusive. No more than 12 of the 40 subjects may have a grade of 3 or 3+ on one or both sides.~5. Females of childbearing potential must have negative urine pregnancy test prior to enrollment and use highly effective birth control methods during study participation and for 8 weeks following the last dose of ACE-083. Males must agree to use a condom during any sexual contact with females of childbearing potential while participating in the study and for 8 weeks following the last dose of ACE-083, even if he has undergone a successful vasectomy.~6. Ability to adhere to the study visit schedule/procedures, and to understand and comply with protocol requirements~7. Signed written informed consent~Key Exclusion Criteria~1. History of active malignancy, with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or ≤ 2 squamous cell carcinomas of the skin~2. Symptomatic cardiopulmonary disease, significant functional impairment, significant orthopedic or neuropathic pain, or other co morbidities that in the opinion of the investigator would limit a patient's ability to complete strength and/or functional assessments on study~3. Type 1 or type 2 diabetes mellitus~4. Thyroid disorder unless condition is stable with no change in treatment for at least 4 weeks before the first dose and no expected change for duration of study~5. Renal impairment (serum creatinine ≥ 2 times the upper limit of normal (ULN\])~6. Aspartate transaminase (AST) and/or alanine transaminase (ALT) ≥ 3 times ULN~7. Increased risk of bleeding (i.e., due to hemophilia, platelet disorders, or use of any anticoagulation/platelet modifying therapies up to 2 weeks prior to Study Day 1 and for duration of study; low dose aspirin \[≤ 100 mg daily\] is permitted)~8. Severe deformity or ankle fixation that would sufficiently limit passive range of motion to affect assessment of dorsiflexion strength~9. Major surgery within 4 weeks prior to Study Day 1~10. Chronic pharmacologic doses of systemic corticosteroids (≥ 2 weeks) within 4 weeks before Study Day 1 and for duration of study; intra-articular/topical/inhaled/intranasal physiologic doses of systemic corticosteroids are permitted~11. Androgens, growth hormone, insulin or oral hormone replacement therapy within 6 months before Study Day 1 and for duration of study; topical physiologic androgen replacement is permitted~12. Any change in medications potentially affecting muscle strength or function within 4 weeks of Study Day 1 and for duration of study (e.g., creatinine, CoQ10, systemic beta-adrenergic agonists)~13. Previous exposure to any investigational agent potentially affecting muscle volume, muscle strength, or muscle or nerve function within 5 half-lives of last dose plus an additional 8-week washout period (or 12 weeks prior to Study Day 1 if half-life is unknown)~14. Any previous or current exposure to ACE-083~15. Significant change in physical activity or exercise (e.g., significant increase or decrease in intensity or frequency) within 8 weeks before Study Day 1 or inability to maintain the baseline level of physical activity throughout the study~16. Any condition that would prevent MRI scanning or compromise the ability to obtain a clear and interpretable scan of the lower leg, as applicable (e.g., knee/hip replacement metallic implants)~17. Known active substance abuse, including alcohol~18. History of sensitivity to protein pharmaceuticals~19. Female that is lactating/breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 Cohort 1 (Type: EXPERIMENTAL): ACE-083 150 mg intramuscular (IM) (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
- Part 1 Cohort 2 (Type: EXPERIMENTAL): ACE-083 200 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
- Part 1 Cohort 3 (Type: EXPERIMENTAL): ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
- Part 2 (double-blind placebo controlled) (Type: EXPERIMENTAL): ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses
- Part 2 (open label) (Type: EXPERIMENTAL): ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 8 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy